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Abstract
Background:  Cellulose acetate phthalate (CAP) has been used for several decades in the
pharmaceutical industry for enteric film coating of oral tablets and capsules. Micronized CAP,
available commercially as "Aquateric" and containing additional ingredients required for
micronization, used for tablet coating from water dispersions, was shown to adsorb and inactivate
the human immunodeficiency virus (HIV-1), herpesviruses (HSV) and other sexually transmitted
disease (STD) pathogens. Earlier studies indicate that a gel formulation of micronized CAP has a
potential as a topical microbicide for prevention of STDs including the acquired immunodeficiency
syndrome (AIDS). The objective of endeavors described here was to develop a water dispersible
CAP film amenable to inexpensive industrial mass production.
Methods: CAP and hydroxypropyl cellulose (HPC) were dissolved in different organic solvent
mixtures, poured into dishes, and the solvents evaporated. Graded quantities of a resulting selected
film were mixed for 5 min at 37°C with HIV-1, HSV and other STD pathogens, respectively.
Residual infectivity of the treated viruses and bacteria was determined.
Results: The prerequisites for producing CAP films which are soft, flexible and dispersible in
water, resulting in smooth gels, are combining CAP with HPC (other cellulose derivatives are
unsuitable), and casting from organic solvent mixtures containing ≈50 to ≈65% ethanol (EtOH). The
films are ≈100 µ thick and have a textured surface with alternating protrusions and depressions
revealed by scanning electron microscopy. The films, before complete conversion into a gel, rapidly
inactivated HIV-1 and HSV and reduced the infectivity of non-viral STD pathogens >1,000-fold.
Conclusions: Soft pliable CAP-HPC composite films can be generated by casting from organic
solvent mixtures containing EtOH. The films rapidly reduce the infectivity of several STD
pathogens, including HIV-1. They are converted into gels and thus do not have to be removed
following application and use. In addition to their potential as topical microbicides, the films have
promise for mucosal delivery of pharmaceuticals other than CAP.
Background
Polymers, used in the past as pharmaceutical excipients
and in drug delivery, are increasingly being considered for
specific therapeutic and prophylactic applications [1-5].
They appear promising for topical applications as micro-
bicides to prevent infection by sexually transmitted dis-
ease (STD) pathogens, including the human
immunodeficiency virus (HIV-1) [6]. One of these prom-
ising polymeric microbicides is cellulose acetate phthalate
(CAP) [7-14]. CAP has been used for enteric film coating
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of tablets and capsules [15] and thus has a well-estab-
lished safety record for human use. CAP is not soluble in
water at pH <≈5.8. For this reason, it must be used in a
micronized form for both tablet coating from water dis-
persions, and as a topical microbicide. Micronization is
accomplished by pseudolatex emulsion processes [16-
24]. A micronized form of CAP available commercially
under the trade name "Aquateric" (FMC Corporation,
Philadelphia, Pennsylvania, USA) (containing 63 to 70%
CAP, Poloxamers and acetylated monoglycerides) in
appropriate gel formulations was shown to inactivate
HIV-1 and several other STD pathogens in vitro and in ani-
mal models [7-9,14]. Micronized CAP was shown to be
the only candidate microbicide having the capacity to
remove rapidly by adsorption HIV-1 from physiological
fluids and render the virus noninfectious.
Microbicidal gels with or without contraceptive activity
have some disadvantages. They need applicators for topi-
cal delivery adding to cost [25] and generating disposal
problems. Furthermore distinct applicator dimensions
may be preferred by distinct populations, and their pack-
aging and size may not be optimal for discretion related
to purchase, storage and use. Microbicidal gel production
and applicator manufacture are likely to occur at different
sites, and high capacity applicator filling equipment is
required for large volume production. These drawbacks
can be overcome by unit dose biodegradable films dis-
persible in water and having the following properties: 1)
the microbicidal activity is a built-in property of the films,
i.e. the active ingredient is an integral structural compo-
nent of the films; 2) the films absorb physiological fluids
and then disintegrate; 3) infectious agents bind to the
resulting structures and become rapidly inactivated; 4) the
films are converted into a soft gel which does not have to
be removed; 5) simplicity of use and no "messiness"; 6)
small packaging, facilitating discretion related to pur-
chase, storage and portability; 7) low production price
and suitability for use in developing countries; 8) amena-
bility to industrial mass production; 9) Integration of
manufacture and packaging; 10) Low cost of transporta-
tion due to the small size and weight of a unit dosage; 11)
capacity to augment a healthy acidic vaginal environment
and 12) potential for modifications leading to their appli-
cation as rectal microbicides. A device having most of
these properties is a sponge prepared by freeze-drying a
foam generated from a water suspension of Aquateric in a
solution of bioadhesive partially substituted ethers of cel-
lulose (e.g. hydroxypropyl methylcellulose, methylcellu-
lose, hydroxyethyl cellulose and hydroxypropyl cellulose
(HPC). Alternatively, the sponges can be prepared by
freeze-drying a microemulsion [26] of CAP in ethyl ace-
tate mixed with a water solution of one of the cellulose
ethers. These sponges contained 34 to 40% of the active
ingredient, CAP. The advantages of the unit dose sponges
are extenuated by the relatively high cost of freeze-drying.
This would limit their use as a microbicide in developing
countries. Therefore, alternative approaches had to be
explored, the objective being the development of a unit
dose water dispersible device, the production of which
does not require freeze drying.
Water soluble or dispersible films are being used for drug
delivery onto mucosal surfaces [27-30]. Films are also an
established delivery vehicle for the administration of vag-
inal products. Contraceptive films have been marketed
since the 1980's and there have been no concerns about
the safety of this method of administration. There was an
86% compliance with film use in a phase III human effi-
cacy trial of a contraceptive film containing Nonoxynol-9
(N-9). Although the trial failed due to the undesirable
properties of N-9, the very high compliance rate shows
that films represent a microbicide delivery method which
is easy and acceptable [31-34]. These findings have led us
to develop CAP based microbicidal films.
The HIV-1 epidemic is maintained and progresses mostly
due to sexual transmission of the virus [35] and is facili-
tated by prior infections with non-viral STD pathogens
[36-40] and herpesviruses (HSV) [41-43]. The estimated
annual worldwide incidence of non-viral STD pathogens
is over 330 million [44]. About 20 % of the United States
population has been infected with HSV-2, the prevalence
of such infections being even higher in developing coun-
tries [45]. Organisms associated with bacterial vaginosis
(BV) also increase the susceptibility to HIV-1 infection
[46]. For these reasons, broad spectrum microbicides act-
ing not only against HIV-1 but also against other STD
pathogens would be expected to have the greatest impact
in preventing STDs including AIDS. Micronized CAP was
shown to act in vitro [7,10-14,47-49] and in some animal
model systems [8,9] as a compound with broad spectrum
activities. This had to be confirmed for the film formula-
tion of CAP.
Methods
Preparation and physical properties of CAP-HPC film
CAP, HPC (150–400 cps, NF, Spectrum, New Brunswick,
New Jersey, USA), HPC (4,000–6,500 cps, NF, Spectrum)
and glycerol were dissolved in acetone-ethanol (EtOH)
4:6 at final concentrations of 2, 1, 1, and 1 % (w/w),
respectively. The viscous liquids were poured into Teflon®
coated steel or aluminum foil dishes (0.425 g/cm2) which
were subsequently kept for 16 hr at 40°C followed by 1 hr
in a vacuum oven at 50°C to dry the films.
To measure the kinetics of film conversion into a gel, the
film was shredded into ≈1 mm2 pieces in a Guardian
Cross-Cut Shredder (Quartet GBC, Skokie, Illinois, USA)
and added at 75 mg/ml to either water or human seminalBMC Infectious Diseases 2003, 3 http://www.biomedcentral.com/1471-2334/3/27
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fluid (New England Immunology Associates, Cambridge,
Massachusetts, USA). Viscosity was measured in a DV-3 P
R digital viscometer (Anton Paar GmbH, Graz, Austria)
using a TR-8 spindle at speeds decreasing from 200 to 2
r.p.m.
Imaging of cast films was performed with a JEOL 6500
Field Emission scanning electron microscope (JEOL USA,
Inc., Peabody, Massachusetts, USA) at a magnification of
5,000 ×. Scanning white light interferometric microscopy
was performed on both sides of the film at a magnifica-
tion of 25 × (Fig. 1b,1c). CAP particles obtained after com-
plete dispersion of the film were pelleted by
centrifugation at 10,000 × g for 5 min, washed with water
to remove excess HPC, and freeze dried. The particles were
dispersed in water and measured by automated scanning
electron microscopy using a JEOL 6400 scanning electron
microscope coupled with a NORAN Voyager system
(NORAN Instruments, Inc., Middleton, Wisconsin, USA).
Imaging of the particles on a carbon substrate was per-
formed using the JEOL 6500 electron microscope.
Measurements of infectivity of HIV-1 and herpesviruses 
(HSV)
To measure HIV-1 infectivity, virus was precipitated from
tissue culture media containing 10% fetal bovine serum
with polyethylene glycol 8000 (final concentration 10
mg/ml). The pellet containing virus was dissolved in 225
µl aliquots of 0.14 M NaCl, 0.01 M Tris(hydroxyme-
thyl)aminomethane, pH 7.2 (TS). The aliquots were pre-
warmed to 37°C and precut pieces of film H were added.
After 5 min at 37°C, 1.225 ml of tissue culture medium
was added and the mixtures were centrifuged for 1 hr at
14,000 r.p.m. in an Eppendorf 54156 microfuge (Brink-
mann Instruments, Inc., Westbury, New York, USA) to
pellet the virus. The virus was redissolved, serially diluted
twofold (2 × to 2,048 ×), and the dilutions tested for infec-
tivity using HeLa-CD4-LTR-β-gal and MAGI-CCR5 cells
for HIV-1 IIIB and HIV-1 BaL, respectively. Virus replica-
tion was quantitated by measuring β-galactosidase (β-gal)
activity in cell lysates as described elsewhere in detail [14].
In a parallel series of experiments, residual film H was
removed by centrifugation at 2,000 r.p.m. for 5 min from
the film-virus mixtures before pelleting the virus at 14,000
r.p.m. The infectivities of control and film H treated HSV-
1 and HSV-2, respectively, were measured under similar
conditions as described for HIV-1 [7]. HSV-1 was a recom-
binant virus, vgCL5, in which the expression of β-gal is
under the control of the late gene C regulatory region.
Vero cells were used for infection which was monitored by
measuring  β-gal activity. ELVIS HSV cells (Diagnostic
Hybrids, Inc., Athens, Ohio, USA), containing a LacZ gene
placed behind an inducible HSV promoter, were used for
infection by HSV-2. Infection was determined by measur-
ing β-gal.
Inactivation of non-viral STD pathogens and bacteria 
associated with bacterial vaginosis (BV)
The bacterial strains and the corresponding growth media
were obtained from the American Type Culture Collection
(ATCC, Manassas, Virginia, USA) and were the same as
described earlier [7,10]. Mycoplasma capricolum was ATCC
#23205. Graded quantities of film H (0 to 150 mg/ml)
were added to suspensions of the respective bacteria (8 ×
108 to 1 × 109/ml in TS) pre-warmed to 37°C. After 5 min
at 37°C, the suspensions were diluted 10-fold in the
appropriate growth medium, centrifuged to pellet the bac-
teria which were then resuspended in the original volume
of growth medium. Serial 10-fold dilutions in the appro-
priate growth media were made, and after incubation at
37°C (30°C for Haemophilus ducreyi) for 20 hr to 5 days,
depending on the bacterial strain, turbidity was measured
at 600 nm. Serial twofold dilutions (100 µl) of control
and film H treated Chlamydia trachomatis were added to 9
× 104 McCoy cells plated into wells of 96-well microtiter
plates. After 48 hr, the cells were fixed and stained with
fluorescein isothiocyanate labeled monoclonal antibod-
ies to Chlamydia (Diagnostic Hybrids) and the fluorescent
inclusion bodies were counted following the procedures
provided by the manufacturer. The percentages of residual
infectivity for each film treated organism were calculated
by comparing the respective dose response curves with
readout vs. dilution curves corresponding to each of the
respective control organisms.
Results
Casting of CAP films
CAP is moisture sensitive during long term storage [15].
Therefore, organic solvents had to be used for film casting.
This appeared counterintuitive since CAP films cast from
organic solvents are water resistant [15], and start dissolv-
ing only at pH > ≈5.8. Furthermore, none of the mucoad-
hesive cellulose ethers are soluble in organic solvents
which dissolve CAP [15], except for HPC which is soluble
in methylene chloride [50]. HPC is also one of the best
bioadhesive polymers among cellulose ethers [51]. It was
possible to prepare composite CAP (40%) – HPC (40%)
– glycerol (20%) films cast from one of the following sol-
vents: ethyl acetate; glacial acetic acid; methylene chlo-
ride; and acetone/EtOH 9:1 (v/v). The resulting films were
hard, brittle and did not disperse in water. It has been
reported that the properties of films cast from organic sol-
vents may change by varying the composition of solvent
mixtures even though the composition of the dried films
is the same [52-56]. Using this approach, we found, sur-
prisingly, that addition of EtOH (final concentrations 50
to 65%) to the casting solvents ethyl acetate, CH3COOH
and acetone, respectively, resulted in films with dramati-
cally altered properties. They were soft, flexible, and dis-
persed in water, resulting ultimately in smooth gels. The
properties of a selected film (designated "H') consisting ofBMC Infectious Diseases 2003, 3 http://www.biomedcentral.com/1471-2334/3/27
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Morphology of CAP-HPC composite film H and of particles after film dispersion in water Figure 1
Morphology of CAP-HPC composite film H and of particles after film dispersion in water. a, Scanning electron microscopy of 
film H (side "A" exposed to air during drying). b, 3-dimensional (3-D) interactive display of side "A" of film H. c, 3-D interactive 
display of film H (side "B" in contact with the casting surface during drying). b, c, Color bar corresponds to elevation scale. d, 
Kinetics of conversion of shredded film H into a gel as measured by increase of viscosity. e, Scanning electron microscopy of 
CAP particles from the gel. f, Size distribution of the particles. Scale bar for a and e is 1 µ.
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40% CAP, 40% HPC and 20% glycerol cast from acetone/
EtOH 4:6 are described here.
Physical properties of CAP-HPC film H
Scanning electron microscopy of film H (thickness ≈100
µ) revealed a particle-accumulated layer on one side (A;
exposed to air during drying) of the film (Fig. 1a) while
the other side was more smooth (results not shown). Side
A of the film was textured with alternating protrusions
and depressions having a lateral dimension of ≈1 µ. The
3-dimensional interactive display of both sides of the film
(Fig. 1b,1c), analogous to a geographic map showing
peaks and valleys, provides a 3-dimensional image of the
film. It covers a larger representative surface of the film
than does Fig. 1a, and clearly indicates that the surface of
the film is not smooth. This is important for the virus
inactivating properties of the film before it disintegrates,
since the effectiveness of the film in this regard depends
on its total surface area accessible to bind viruses or other
pathogens. This area is much larger for a film with eleva-
tions and depressions (which can accommodate virus par-
ticles) as compared with a film which is "truly" flat.
Exposure of the film to water resulted in disintegration
and formation of smaller particles ultimately convertible
into a gel. Mixing of pieces of film in water at low speed
resulted in generation of a smooth gel. The only method
to measure objectively the kinetics of this transition is vis-
cosimetry. The corresponding results are shown in Fig. 1d.
The conversion to gel was faster in seminal fluid than in
water. Scanning electron microscopy revealed particles of
micronized CAP in the resulting gel (Fig. 1e). The particles
had a size between 0.5 to 3 µ (Fig. 1f), similar to that of
CAP particles in gel formulations which were shown to be
efficacious against several STD pathogens in in vitro and in
vivo experiments [7,10-14,47-49].
Microbicidal activities of CAP-HPC film
Micronized CAP was shown to inactivate within a few
minutes the infectivity of HIV-1, HSV and several non-
viral STD pathogens [7,14]. CAP in micronized form is the
only candidate topical microbicide having the capacity to
remove rapidly by adsorption from physiological fluids
HIV-1 of both the X4 and R5 biotypes and is likely to pre-
vent virus contact with target cells [14]. The efficiency of
adsorption is proportional to the total surface area of the
adsorbent. For a given quantity of adsorbent the surface
area is a function of particle size of the adsorbent, the total
surface of the particles being inversely proportional to
particle diameter, i.e. the smaller the particles, the larger is
the total surface area of all particles. For this reason, it is
desirable that the film disintegrates into the smallest par-
ticles possible.
It was of interest to determine whether film H, long before
it completely disintegrates in the presence of water, and is
converted into a gel, has effects similar to those of micro-
nized CAP. Weighed film aliquots were added to suspen-
sion of the respective viruses. After incubation for 5 min
at 37°C, the infectivity of the residual viruses was deter-
mined by serially diluting each virus preparation and add-
ing the respective diluted samples to target cells. Virus
production was assessed using a luminescence readout
system. Film was not added to control virus preparations
(for details see Methods section). Dose response curves
(i.e. luminescence vs. virus dilution) for all film treated
and control viruses are shown in Fig. 2. The percentages of
virus inactivated by the film were calculated from calibra-
tion curves relating luminescence to dilutions of each con-
trol virus (=red curves for each virus; Fig. 2). At the highest
dose of film (56 mg/ml) ≥ 99% inactivation of HIV-1,
HSV-1 and HSV-2 was observed within 5 min at 37°C
(Fig. 2a,2b,2c,2d). Both HIV-1 IIIB and BaL, viruses utiliz-
ing distinct cellular coreceptors, CXCR4 and CCR5,
respectively [12], were inactivated. As the film dose was
reduced, the extent of virus inactivation diminished and
was 89 ± 4, 82 ± 9, 99.7 ± 0.1, and 95 ± 2 % for HIV-1 IIIB,
HIV-1 BaL, HSV-1 and HSV-2, respectively, at a dose of 7
mg/ml. The residual infectivity in all cases was recovered
in supernatants after removing film and particles released
from it by centrifugation, suggesting that only virus not
adsorbed to the film material escaped inactivation. This
was confirmed in separate experiments (data not shown).
For comparison, the suggested unit dose of film as a
microbicide is ≈ 1,000 mg. Furthermore, under in vivo
conditions (when the virus concentrations are expected to
be by one to four orders of magnitude lower than those
used here under experimental conditions [57,58], virus
removal by adsorption onto the insoluble CAP would be
expected to block the complex sequence of events leading
to mucosal infection. This would be further augmented by
the formation of "dead-end" HIV-1 gp41 six-helix bundles
and stripping off of HIV-1 envelope glycoproteins result-
ing from virus contact with CAP [14].
Film H also inactivated several non-viral STD pathogens
and bacteria associated with BV (Fig. 3). This effect can be
attributed to low pH provided by CAP [7,10], unlike the
anti-HIV-1 and anti-HSV-1/-2 effects occurring at both
acidic and neutral pH [7,13,14]. This is probably reflected
in the diminishing activity of the film as its dose is
decreased. While the residual infectivity of all organisms
tested was ≤ 0.1% for film doses ≥ 75 mg/ml (≥ 27.7 mg/
ml for Chlamydia trachomatis), smaller film doses were
much less effective (notice the logarithmic scale of the
ordinate). Gardnerella vaginalis appeared to be the most
sensitive to CAP among all organisms tested. The dose
effect was not seen for Haemophilus ducreyi, suggesting dis-
tinct mechanisms of CAP action on different bacteria.BMC Infectious Diseases 2003, 3 http://www.biomedcentral.com/1471-2334/3/27
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Discussion
To the best of our knowledge, the CAP film is presently the
first film formulation for a candidate microbicide after the
failure of an N-9 containing contraceptive film in phase III
clinical trials for efficacy against sexual transmission of
HIV-1. The likelihood of genital lesions after vaginal
application of this film has been reported [31,59]. This
has led to the misconception among some researchers in
the microbicide field that films, rather than the film ingre-
dients, are responsible for the untoward effects observed.
In fact, undesirable proinflammatory effects induced by
N-9 have been documented in in vitro experiments [60,61]
and in cervicovaginal lavages from women after applica-
tion of an N-9 containing gel [60,61]. Inflammatory
responses induced by N-9 were seen in animal model
experiments [62]{S. Hild personal communication} and
in women after vaginal application of N-9 [32,63,64]. On
the other hand, untoward effects have not been seen when
CAP was used in in vitro [61] or animal model experi-
ments [65] (S. Hild, personal communication). CAP
based gels have received regulatory approval in the United
Kingdom for phase I clinical trials based on the latter find-
ings. Thus, there is a priori no reason to believe that CAP
films will elicit undesirable effects.
Difficulties in applying the N-9 film have been reported
anecdotically since the film appeared to stick to wet fin-
gers. This does not seem to apply to CAP films. The opti-
mization of CAP films in iterative human acceptance trials
is expected to obviate problems of this kind.
Inactivation of HIV-1 IIIB, HIV-1 BaL and HSV-1 and HSV-2 by graded quantities of film H Figure 2
Inactivation of HIV-1 IIIB, HIV-1 BaL and HSV-1 and HSV-2 by graded quantities of film H. Serial dilutions of the respective con-
trol and film treated (5 min at 37°C) viruses were added to cells and virus replication was monitored by measuring β-gal 
activity.
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The CAP-HPC composite film after contact with water or
physiological fluids is progressively converted into a gel
(Fig. 1d). Similar gels were shown earlier [7,8,12-14] to
rapidly inactivate HIV-1, HSV and other STD pathogens.
Upon contact with fluids containing STD pathogens, the
film inactivated the respective viruses and/or bacteria rap-
idly, long before it was converted into a gel. Expected
exposure to high sheer rates during physiological proc-
esses would result in more rapid disintegration and
conversion of the film into a gel than shown in Fig. 1d.
Tests in animal model systems and human clinical trials
will be needed to determine whether the film is effica-
cious in vivo.
Similarly to CAP based gels [10], the CAP-HPC film was
active against several bacteria associated with BV, known
to increase susceptibility to HIV-1 infection [46]. Thus
inserted CAP-HPC films might be candidates for treat-
ment of BV.
In addition to their application as a topical microbicide
the described bioadhesive CAP-HPC films could be useful
for delivery of pharmaceuticals to mucosal surfaces,
including oral and ophthalmic [66,67] applications.
Scaling up the film production on continuous belts, the
selection of optimal size, thickness, shapes, folding, and
appropriate packaging of the films for distinct applica-
tions will require further studies.
Inactivation by film H of selected non-viral STD pathogens and bacteria associated with BV Figure 3
Inactivation by film H of selected non-viral STD pathogens and bacteria associated with BV. The STD pathogens (Neisseria gon-
orrhoeae, Haemophilus ducreyi and Chlamydia trachomatis) and bacteria associated with BV (Gardnerella vaginalis, Mycoplasma cap-
ricolum and Mycoplasma hominis) were treated with graded quantities of film H for 5 min at 37°C. Note on the abscissa that film 
dosages for Chlamydia trachomatis were different from those used for the other bacteria.
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The CAP-HPC composite can be dried from organic sol-
vent mixtures containing EtOH (as described above) in
physical forms other than a film, e.g. granules, combined
with tablet disintegrants (Mannogem or Pharmaburst [SPI
Pharma, Grand Haven, MI, USA]) and compressed into
tablets. The tablets in contact with water disintegrate
instantaneously and are subsequently converted into a
smooth gel similar to that generated by the films (Fig. 1d).
Such tablets extend the potential application of the CAP-
HPC composite as a topical microbicide and drug delivery
tool. In general, the described composite contributes to
broadening the function of CAP from an enteric coating
material to becoming a component of novel mucosal drug
delivery systems with inherent anti-microbial properties.
Conclusions
Microbicidal gels are being widely considered and devel-
oped as tools to prevent the sexual transmission of HIV-1
and other STD pathogens. A CAP based gel for this pur-
pose has been developed [7-14] and is advancing into
phase 1 human clinical trials. Such gels require applica-
tors for topical delivery. This adds to the cost of the final
product and may cause disposal problems and environ-
mental concerns. These disadvantages can be overcome by
replacing the gels with unit dose biodegradable devices
dispersible in physiological fluids. We describe here a
novel method to produce composite films in which the
active ingredient, CAP, is an integral structural compo-
nent. The film absorbs water and disintegrates leading to
the formation of micronized CAP particles which were
shown to adsorb HIV-1 [14] and inactivate STD patho-
gens. The film is converted in contact with physiological
fluids into a soft gel, thus obviating the need for delivery
by applicators. The CAP-HPC composite film could be
useful for delivery to mucosal surfaces of pharmaceuticals
other than CAP. Combined with other excipients, the
shredded composite film can be compressed into tablets
which disintegrate instantaneously, providing an alterna-
tive microbicide and general drug delivery system.
Abbreviations used
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ficiency virus; HSV, herpes viruses; STD, sexually transmit-
ted disease; AIDS, acquired immunodeficiency syndrome;
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galactosidase; BV, bacterial vaginosis.
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